BY SEAN WHOOLEY rthofix Medical (Nasadaq: OFIX)+ today announced new data investigating pulsed electromagnetic field (PEMF) stimulation with lumbar spinal fusion. Lewisville, Texas-based Orthofix evaluated PEMF stimulation as an adjunct to lumbar spinal fusion procedures in patients at risk for pseudoarthrosis. Patients treated with the SpinalStim bone growth device demonstrated a high rate of successful fusion. They also showed significant improvements in pain, function and quality of life, despite having risk factors for pseudoarthrosis. SpinalStim, an FDA-approved bone growth stimulation therapy, offers an adjunct treatment for lumbar spinal fusion. It also functions as a nonsurgical treatment for spinal pseudoarthrosis. The device utilizes PEMF technology that provides 360 degrees of treatment coverage around the fusion site. Orthofix says its system has an overall success rate of 92% in treating spinal fusion surgery patients. Researchers published their data evaluating the SpinalStim system in the International Journal of Spine Surgery. Lead author Dr. ...
Dr. Lionel Piroth and Dr. Marine Jacquier from the Centre Hospitalier Universitaire in Dijon reported in the New England Journal of Medicine, “A 35-year-old French woman presented to the emergency department with weakness, a feeling of electric shocks in both legs, and repeated falls; She reported that the symptoms had been progressing, and she noted that she had had difficulty riding her horse for the preceding three months.”
Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report.
Camber Spine Technologies' Spira open matrix anterior lumbar interbody fusion device won FDA clearance from the FDA.
Shanghai, China & JERSEY CITY, N.J. – April 8, 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX14. The agreement covers markets such as the United States, the European Union, and Canada. An exception from the agreement is China. The randomized, double-blind, international multicenter, parallel-controlled phase 3 clinical study (NCT05352516) aimed to compare the efficacy, safety, tolerability, and immunogenicity of HLX14 with EU-sourced reference denosumab (Prolia®) in postmenopausal women with osteoporosis at high risk for fracture. Eligible patients were randomised at a 1:1 ratio to receive subcutaneous injection of 60 mg of HLX14 or reference denosumab (Prolia®) every six months. The primary efficacy endpoint ...
Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, originate in hormone-releasing cells and can develop in various organs, including the prostate and lungs. While they are not the most prevalent cancer type in these organs, they often have a poor prognosis and limited therapeutic options. Current treatments for these cancers include chemotherapy, radiation, and immunotherapy combinations. Neuroblastoma, predominantly found in young children, develops from immature nerve cells, often in the adrenal glands or nerve tissue along the spine, chest, abdomen, or pelvis. Despite treatment efforts, these therapies only extend survival by a few months, underscoring the need for better therapeutic targets and less invasive diagnostic approaches for these malignancies. Investigators from the UCLA Health Jonsson Comprehensive Cancer Center (Los Angeles, CA, USA) have identified UCHL1, a protein found in aggressive neuroendocrine carcinomas and neuroblastoma, as a potential molecular biomarker for diagnosing these cancers and predicting and monitoring ...
Globus Medical is laying off staff after the company merged with spine specialist Nuvasive. In California alone, the company is cutting more than 150 positions, according to documents reviewed by MedTech Dive. Nuvasive said it “will be laying off a number of its employees” in San Diego, where it was headquartered, according to a Jan. 3 notice shared with MedTech Dive by the California Employment Development Department. The affected employees were notified in the first week of January, and their last day of employment will be March 5, according to the document. Nuvasive’s San Diego office will remain open. A Globus spokesperson said the company is restructuring but declined to say how many positions were affected. “As part of our ongoing integration, we recently announced some organizational restructuring across the combined company in support of our committed synergy delivery,” the spokesperson wrote in an email. The California notice included a ...
CMEF(full name: China International Medical Equipment Expo) was founded in 1979, held twice a year in the spring and autumn, after more than 40 years of innovation and development, has become the world's leading covering the whole industry chain, scientific and technological innovation, new product launch, business docking, brand communication, academic exchange, trend insight, education and training in one of the medical health technology platform. With the theme of "Innovation and Technology leading the Future", this year's CMEF covers tens of thousands of whole-department and whole-industry chain product technologies and solutions for medical imaging, in vitro diagnosis, medical electronics, medical optics, hospital construction, operating room, disinfection sensor control, medical consumables, orthopedic medical robots, etc.
Researchers from the French National Institute of Health and Medical Research, the French National Center for Scientific Research and the University of Bordeaux in France, along with Swiss researchers and neurosurgeons, have successfully designed and tested a spinal stimulation implant to treat Parkinson’s disease. Conducted in collaboration with the Swiss Federal Institute of Technology in Lausanne and the Lausanne university and hospital (UNIL CHUV), the implant was tested to correct disabling gait disorders, which are associated with 90% of people living with advanced Parkinson’s and are often resistant to treatment. Parkinson’s disease is a neurodegenerative condition which progressively damages and leads to a loss of nerve cells in parts of the brain. Gait disorders are commonly caused by weakness of the hip and lower extremity muscles, such as cerebral palsy, muscular dystrophy and spinal muscular dystrophy. The implant directly stimulates nerve cells in the spinal cord responsible for controlling leg ...
BY SEAN WHOOLEY The Mobi-C cervical disc. ZimVie (Nasdaq: ZIMV)+ announced today that the first U.S. patient received its new 4.5mm Mobi-C cervical disc. Mobi-C became the first cervical disc approved for one and two levels by the FDA in 2013. Ten years later, in August of this year, ZimVie picked up FDA approval for a smaller height for the device. The updated 4.5mm Mobi-C comes in seven footprints to match patient anatomy. Dr. Gregory D. Lopez of Midwest Orthopaedics at Rush in Chicago implanted the first of these devices in the U.S. on Oct. 30. “The 59-year-old patient presented with a significantly collapsed C5-6 disc, and the new lower profile Mobi-C implant allowed me to avoid over-distracting the facet joints,” Lopez said in a news release. “The 4.5mm height Mobi-C makes it possible for me to offer pain relief and motion preservation to more of my patients with cervical ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.